|
KMID : 1240020170210010053
|
|
International Neurourology Journal
2017 Volume.21 No. 1 p.53 ~ p.61
|
|
|
Efficacy and Adverse Events Associated With Use of OnabotulinumtoxinA for Treatment of Neurogenic Detrusor Overactivity: A Meta-Analysis
|
|
Yuan Hejia
Cui Yuanshan
Wu Jitao
Peng Peng
Sun Xujie
Gao Zhenli
|
|
|
Abstract
|
|
|
Purpose: OnabotulinumtoxinA is used widely for the treatment of neurogenic detrusor overactivity. We conducted a systematic review and meta-analysis to assess its efficacy and safety for neurogenic detrusor overactivity treatment.
Methods: A systematic literature review was performed to identify all published randomized double-blind, placebo-controlled trials of onabotulinumtoxinA for neurogenic detrusor overactivity treatment. MEDLINE, Embase, and the CENTRAL were employed. Reference lists of retrieved studies were reviewed carefully.
Results: Six publications involving 871 patients, which compared onabotulinumtoxinA with a placebo were analyzed. Efficacy of onabotulinumtoxinA treatment was shown as a reduction of the mean number of urinary incontinence episodes per day (mean difference, -1.41; 95% confidence interval [CI], -1.70 to -1.12; P<0.00001), maximum cystometric capacity (135.48; 95% CI, 118.22?152.75; P<0.00001), and maximum detrusor pressure (-32.98; 95% CI, -37.33 to -28.62; P<0.00001). Assessment of adverse events revealed that complications due to onabotulinumtoxinA injection were localized primarily to the urinary tract.
Conclusions: This meta-analysis suggests that onabotulinumtoxinA is an effective treatment for neurogenic detrusor overactivity with localized advent events.
|
|
|
KEYWORD
|
|
|
Neurogenic Detrusor Overactivity, OnabotulinumtoxinA, Meta-Analysis, Randomized Controlled Trial
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
 
|